The role of alectinib in the treatment of advanced non‑small cell lung cancer


MUDr. Daniel Krejčí; MUDr. Jana Krejčí; MUDr. Petr Opálka, CSc., MBA; MUDr. Bc. Petr Zůna; doc. MUDr. Norbert Pauk, CSc.

Klinika pneumologie 3. LF UK a Nemocnice Na Bulovce, Praha



Despite a small percentage of these patients, the issue of patients with a positive mutation in the anaplastic lymphoma kinase (ALK) gene is highly debated. Alectinib demonstrated a statistically significant prolongation of progression-free time and an excellent therapeutic and preventive effect in the central nervous system in phase III ALEX, J-ALEX and ALUR studies.1-3 At the time of writing, alectinib is fully reimbursed in first-line treatment even after crizotinib failure.4


Key words

alectinib, non-small cell lung cancer



The full article is only available to subscribers

Become a regular subscriber to our Oncological Review...